Recent developments using HDAC inhibitors to treat cancers, ALS, and other neurological diseases show promising results in ameliorating symptoms and highlight the necessity of exploring these new approaches to treat AD (Li et al., 2020; Bondarev et al., 2021). This evidence concerns the gene HDAC9 and Alzheimer disease.